CAJ | 학술논문

目的：评价国产文拉法辛缓释片治疗抑郁症的疗效和安全性。方法随机选取2013年2月1日～2013年11月30日在我院住院的符合CCMD-3诊断标准的抑郁症患者158例为研究对象，口服文拉法辛缓释片（博乐欣），平均剂量150mg ±75mg/日，分别在治疗2、4、6、8周后进行汉密顿抑郁量表（HAMD-17）测评、临床总印象量表（CGI-SI）、药物不良反应量表（TESS）以评价疗效和药物不良反应。体检和辅助检查评价安全性。结果完成8周治疗，汉密顿抑郁量表（HAMD-17）、CGI-SI减分值和减分率差异有显著性（P＜0．05，P＜0．01），文拉法辛缓释片治疗抑郁症的疗效：治愈68．35％，显著进步23．42％，进步6．96％，无效1．27％，不良反应发生率17．72％。结论文拉法辛缓释片治疗抑郁症疗效确切，安全性好，不良反应轻微。
목적：평개국산문랍법신완석편치료억욱증적료효화안전성。방법수궤선취2013년2월1일～2013년11월30일재아원주원적부합CCMD-3진단표준적억욱증환자158례위연구대상，구복문랍법신완석편（박악흔），평균제량150mg ±75mg/일，분별재치료2、4、6、8주후진행한밀돈억욱량표（HAMD-17）측평、림상총인상량표（CGI-SI）、약물불량반응량표（TESS）이평개료효화약물불량반응。체검화보조검사평개안전성。결과완성8주치료，한밀돈억욱량표（HAMD-17）、CGI-SI감분치화감분솔차이유현저성（P＜0．05，P＜0．01），문랍법신완석편치료억욱증적료효：치유68．35％，현저진보23．42％，진보6．96％，무효1．27％，불량반응발생솔17．72％。결논문랍법신완석편치료억욱증료효학절，안전성호，불량반응경미。
Objective To evaluate the efficacy and safety of domestic Venlafaxine sustained-release tablets in the treatment of depression.Methods Randomly select 158 cases of depression patients as the research object (from February 1,2013 to November 30,2013 in our hospital with the diagnosis of CCMD-3).Ask them to take Venlafaxine extended release tablets (Bo Lexin),the average dose of 150mg ±75mg per day.Respectively,after the treatment of 2,4,6,8 weeks after the Hamilton Depression Scale(HAMD -17)assessment,the total clinical impression scale (CGI -SI),drug pay scale (TESS),evaluate the effi-cacy and drug side reaction.Give them physical examinations and auxiliary examination of safety evaluation.Results After 8 -week treatment,the Hamilton De-pression Scale (HAMD -17),CGI -SI score andreduction rate had significant difference (P <0.05,P <0.01).Effects of Venlafaxine sustained release tabletsin the treatment of depression:68.35% were cured,23.42% had significant progress ,6.96% had some progress,1.27% were invalid ,17.72% had sideeffects.Conclusion Venlafaxine sustained -release tablets have curative effect,good security,slight side reaction in the treatment of depression.